WO2022154472A1 - Cd55에 대한 신규 항체 및 이의 용도 - Google Patents
Cd55에 대한 신규 항체 및 이의 용도 Download PDFInfo
- Publication number
- WO2022154472A1 WO2022154472A1 PCT/KR2022/000551 KR2022000551W WO2022154472A1 WO 2022154472 A1 WO2022154472 A1 WO 2022154472A1 KR 2022000551 W KR2022000551 W KR 2022000551W WO 2022154472 A1 WO2022154472 A1 WO 2022154472A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- antigen
- amino acid
- binding fragment
- acid sequence
- Prior art date
Links
- 102100025680 Complement decay-accelerating factor Human genes 0.000 claims abstract description 144
- 101000856022 Homo sapiens Complement decay-accelerating factor Proteins 0.000 claims abstract description 144
- 239000012634 fragment Substances 0.000 claims abstract description 69
- 239000000427 antigen Substances 0.000 claims abstract description 67
- 102000036639 antigens Human genes 0.000 claims abstract description 67
- 108091007433 antigens Proteins 0.000 claims abstract description 67
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 49
- 201000011510 cancer Diseases 0.000 claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 63
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 63
- 229960004641 rituximab Drugs 0.000 claims description 52
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 47
- 238000000034 method Methods 0.000 claims description 27
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 20
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 20
- 229960002411 imatinib Drugs 0.000 claims description 20
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims description 19
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims description 19
- 229960002584 gefitinib Drugs 0.000 claims description 19
- 238000011282 treatment Methods 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 8
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 8
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 8
- 108020004707 nucleic acids Proteins 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 4
- 230000000144 pharmacologic effect Effects 0.000 claims description 4
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 3
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 3
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 3
- 239000003112 inhibitor Substances 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 abstract description 21
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 230000001225 therapeutic effect Effects 0.000 abstract description 17
- 201000010099 disease Diseases 0.000 abstract description 16
- 239000003814 drug Substances 0.000 abstract description 16
- 230000000295 complement effect Effects 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 11
- 206010059866 Drug resistance Diseases 0.000 abstract description 9
- 230000008076 immune mechanism Effects 0.000 abstract description 8
- 229940124597 therapeutic agent Drugs 0.000 abstract description 8
- 239000002671 adjuvant Substances 0.000 abstract description 5
- 230000010534 mechanism of action Effects 0.000 abstract description 4
- 230000001404 mediated effect Effects 0.000 abstract description 4
- 230000004043 responsiveness Effects 0.000 abstract description 4
- 230000002018 overexpression Effects 0.000 abstract description 3
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 230000004614 tumor growth Effects 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 62
- 230000014509 gene expression Effects 0.000 description 35
- 230000006907 apoptotic process Effects 0.000 description 28
- 230000000694 effects Effects 0.000 description 23
- 230000002441 reversible effect Effects 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 17
- 208000006990 cholangiocarcinoma Diseases 0.000 description 17
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
- 230000009977 dual effect Effects 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 238000003556 assay Methods 0.000 description 11
- 238000001514 detection method Methods 0.000 description 11
- 238000012790 confirmation Methods 0.000 description 10
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- 238000010367 cloning Methods 0.000 description 9
- HKZAAJSTFUZYTO-LURJTMIESA-N (2s)-2-[[2-[[2-[[2-[(2-aminoacetyl)amino]acetyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoic acid Chemical compound NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O HKZAAJSTFUZYTO-LURJTMIESA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 210000004102 animal cell Anatomy 0.000 description 7
- 229940088598 enzyme Drugs 0.000 description 7
- 230000002147 killing effect Effects 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 229940041181 antineoplastic drug Drugs 0.000 description 6
- 229910002091 carbon monoxide Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000032839 leukemia Diseases 0.000 description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 6
- SOEGEPHNZOISMT-BYPYZUCNSA-N Gly-Ser-Gly Chemical compound NCC(=O)N[C@@H](CO)C(=O)NCC(O)=O SOEGEPHNZOISMT-BYPYZUCNSA-N 0.000 description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 5
- 239000006091 Macor Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000011260 co-administration Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- WWSJZGAPAVMETJ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethoxypyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)OCC WWSJZGAPAVMETJ-UHFFFAOYSA-N 0.000 description 4
- 208000003950 B-cell lymphoma Diseases 0.000 description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 229920002873 Polyethylenimine Polymers 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 239000012979 RPMI medium Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000035939 shock Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- YXHLJMWYDTXDHS-IRFLANFNSA-N 7-aminoactinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=C(N)C=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 YXHLJMWYDTXDHS-IRFLANFNSA-N 0.000 description 3
- 108700012813 7-aminoactinomycin D Proteins 0.000 description 3
- 108090000672 Annexin A5 Proteins 0.000 description 3
- 102000004121 Annexin A5 Human genes 0.000 description 3
- 101100450694 Arabidopsis thaliana HFR1 gene Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 101100386242 Homo sapiens CD55 gene Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 230000001640 apoptogenic effect Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002301 combined effect Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 201000005787 hematologic cancer Diseases 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- LPZOCVVDSHQFST-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-3-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C(=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2)CC LPZOCVVDSHQFST-UHFFFAOYSA-N 0.000 description 2
- FYELSNVLZVIGTI-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-5-ethylpyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1CC)CC(=O)N1CC2=C(CC1)NN=N2 FYELSNVLZVIGTI-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010008342 Cervix carcinoma Diseases 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 2
- 101150008942 J gene Proteins 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 238000000516 activation analysis Methods 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 108010001064 glycyl-glycyl-glycyl-glycine Proteins 0.000 description 2
- 201000010536 head and neck cancer Diseases 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- HUDPLKWXRLNSPC-UHFFFAOYSA-N 4-aminophthalhydrazide Chemical class O=C1NNC(=O)C=2C1=CC(N)=CC=2 HUDPLKWXRLNSPC-UHFFFAOYSA-N 0.000 description 1
- 102000012440 Acetylcholinesterase Human genes 0.000 description 1
- 108010022752 Acetylcholinesterase Proteins 0.000 description 1
- 239000012103 Alexa Fluor 488 Substances 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010009575 CD55 Antigens Proteins 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108091092584 GDNA Proteins 0.000 description 1
- 101001005360 Homo sapiens Immunoglobulin lambda variable 3-1 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100025921 Immunoglobulin lambda variable 3-1 Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 102220567158 Ornithine decarboxylase antizyme 1_F68A_mutation Human genes 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229940022698 acetylcholinesterase Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 229940124691 antibody therapeutics Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000004057 biotinyl group Chemical class [H]N1C(=O)N([H])[C@]2([H])[C@@]([H])(SC([H])([H])[C@]12[H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000005880 cancer cell killing Effects 0.000 description 1
- FPPNZSSZRUTDAP-UWFZAAFLSA-N carbenicillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C(C(O)=O)C1=CC=CC=C1 FPPNZSSZRUTDAP-UWFZAAFLSA-N 0.000 description 1
- 229960003669 carbenicillin Drugs 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002848 electrochemical method Methods 0.000 description 1
- 210000005168 endometrial cell Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036438 mutation frequency Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000001915 proofreading effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Definitions
- the present invention relates to a novel antibody or antigen-binding fragment thereof specifically recognizing CD55 and a composition for preventing, treating and/or diagnosing cancer using the same.
- the global anticancer drug market has grown at a CAGR of 10 - 13% over the past decade, and is expected to reach a total of $200 billion by 2022.
- CAGR 10 - 13% over the past decade, and is expected to reach a total of $200 billion by 2022.
- 1 in 5 men and 1 in 6 women worldwide will experience cancer at least once in their lifetime, and 1 in 8 men and 1 in 11 women will die from cancer.
- the morbidity and mortality rates are continuously increasing.
- the global anticancer drug market is undergoing a paradigm shift from first-generation chemotherapy to second-generation targeted anticancer drugs and third-generation immune anticancer drugs.
- targeted anticancer treatment technologies that selectively attack only cancer cells without damaging normally rapidly dividing cells are being actively studied.
- Development consists of two steps: the selection of a receptor specifically expressed on the cancer cell and the development of a targeting compound that binds to the receptor, which allows for the selective targeting of the cancer cell.
- CD55 decay-accelerating factor, DAF
- DAF decay-accelerating factor
- solid cancers with high CD55 expression show low therapeutic reactivity to various anticancer drugs whose mechanism of action is complement dependent cytotoxicity (CDC).
- CDC complement dependent cytotoxicity
- Patent Document 1 Republic of Korea Registration No. 10-1800774
- the present inventors have dedicated themselves to developing an excellent CD55 inhibitor that can efficiently restore the immune mechanism inhibited by CD55 by specifically recognizing the CD55 protein, a receptor that suppresses the complement immune mechanism, and specifically inhibiting its activity. research efforts were made. As a result, it was found that complement-mediated cell lysis activity against cancer cells was significantly restored due to significantly increased CD55 binding and inhibitory power when using an antibody substituted with some amino acids of the key antigen recognition site in the variable region. By doing so, the present invention was completed.
- an object of the present invention is an antibody or antigen-binding fragment thereof that specifically binds to CD55; and to provide a composition for preventing or treating and/or diagnosing cancer comprising the same.
- Another object of the present invention is to provide a bispecific antibody comprising an antigen-binding fragment of an antibody that specifically binds to CD55 and an antigen-binding fragment of an antibody that specifically binds to CD20.
- the present invention provides an HCDR1 region having an amino acid sequence represented by the following general formula (1); HCDR2 region having the amino acid sequence of SEQ ID NO: 1; And it provides an antibody or antigen-binding fragment thereof that specifically binds to CD55, comprising a heavy chain variable region comprising an HCDR3 region having an amino acid sequence represented by the following general formula 2:
- X 1 is Ala or Val
- X 2 is selected from the group consisting of Val, Ala, Ile, Leu, Phe and Met.
- the present inventors have dedicated themselves to developing an excellent CD55 inhibitor that can efficiently restore the immune mechanism inhibited by CD55 by specifically recognizing the CD55 protein, a receptor that suppresses the complement immune mechanism, and specifically inhibiting its activity. research efforts were made. As a result, it was found that complement-mediated cell lysis activity against cancer cells was significantly restored due to significantly increased CD55 binding and inhibitory power when using an antibody substituted with some amino acids of the key antigen recognition site in the variable region. did.
- antibody refers to a protein molecule serving as a receptor that specifically recognizes an antigen, including immunoglobulin molecules having immunological reactivity with a specific antigen, and includes polyclonal antibodies and monoclonal antibodies. include all
- Antibodies include antigen-binding fragments (antibody fragments) of antibody molecules as well as full-length antibody forms.
- a complete antibody has a structure having two full-length light chains and two full-length heavy chains, and each light chain is linked to a heavy chain by a disulfide bond.
- the heavy chain constant region has gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ) and epsilon ( ⁇ ) types and subclasses gamma 1 ( ⁇ 1), gamma 2 ( ⁇ 2), gamma 3 ( ⁇ 3). ), gamma 4 ( ⁇ 4), alpha 1 ( ⁇ 1) and alpha 2 ( ⁇ 2).
- the constant region of the light chain has a kappa ( ⁇ ) and a lambda ( ⁇ ) type.
- the term “antigen-binding fragment of an antibody” refers to a fragment that specifically recognizes an antigen within an entire antibody molecule and retains an antigen-antibody-binding function, and includes a single-domain antibody (sdAb), a single-chain antibody (scFv). ), Fab, F(ab'), F(ab')2 and Fv, and the like.
- fragment examples include a monovalent fragment consisting of VL, VH, CL and CH1 domains (Fab fragment); a bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region (F(ab')2 fragment); Fd fragment consisting of VH and CH1 domains; an Fv fragment consisting of the VL and VH domains of one arm of an antibody, and a disulfide-linked Fv (sdFv); a dAb fragment consisting of a VH domain; and separate complementarity determining regions (CDRs) or combinations of two or more separate CDRs optionally followed by a linker.
- Fab fragment monovalent fragment consisting of VL, VH, CL and CH1 domains
- F(ab')2 fragment bivalent fragment comprising two Fab fragments linked by a disulfide bridge at the hinge region
- Fd fragment consisting of VH and CH1 domains
- an Fv fragment consisting of the VL and VH domains of one arm of
- the scFv may be linked by a linker such that the VL and VH regions are paired to form a single protein chain forming a monovalent molecule.
- Such single-chain antibodies are also included in antibody fragments.
- the antibody or fragment of the antibody may be a tetrameric antibody comprising two heavy chain molecules and two light chain molecules; antibody light chain monomers; antibody heavy chain monomers; antibody light chain dimers, antibody heavy chain dimers; Intrabody; monovalent antibody; camel antibody; and single-domain antibodies (sdAbs).
- Fv is a minimal antibody fragment having only a heavy chain variable region and a light chain variable region, and recombinant technology for generating Fv fragments is described in PCT International Patent Application Publications WO 88/10649, WO 88/106630, WO 88/07085, WO 88/07086 and WO 88/09344.
- a double-chain Fv two-chain Fv
- the heavy chain variable region and the light chain variable region are connected by a non-covalent bond
- a single-chain Fv single-chain Fv
- the heavy chain variable region and the single chain variable region are generally shared through a peptide linker.
- Such antibody fragments can be obtained using proteolytic enzymes (for example, by restriction digestion of the entire antibody with papain to obtain Fab, and by digestion with pepsin to obtain F(ab')2 fragments), gene It can also be produced through recombinant technology.
- the term “heavy chain” refers to a variable region domain V H comprising an amino acid sequence having sufficient variable region sequence to confer specificity to an antigen and a full length comprising three constant region domains C H1 , C H2 and C H3 . both heavy chains and fragments thereof.
- the term “light chain” refers to both a full-length light chain including a variable region domain V L and a constant region domain CL including an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen and a fragment thereof. do.
- CDR complementarity determining region
- the scope of the antibody or antibody fragment of the present invention includes variants having conservative amino acid substitutions in the CDR regions, and to the extent that CD55 can be specifically recognized, variants to the amino acid sequences set forth in the accompanying sequence listing are included. can For example, additional changes may be made to the amino acid sequence of the antibody in order to further improve the half-life, biocompatibility, and other biological properties in addition to the binding affinity of the antibody. Considering the variation having such biological equivalent activity, it is construed that the antibody or nucleic acid molecule encoding the same of the present invention includes a sequence showing substantial identity to the sequence listed in the sequence listing.
- the substantial identity is at least 61% when the aligned sequence is analyzed using an algorithm commonly used in the art after aligning the sequence of the present invention and any other sequences as much as possible.
- homology according to one specific example, 70% homology, according to another specific example, 80% homology, according to another specific example, 90% homology.
- Alignment methods for sequence comparison are known in the art. Various methods and algorithms for alignment are described in Smith and Waterman, Adv. Appl. Math . (1981) 2:482 Needleman and Wunsch, J. Mol. Bio . (1970) 48:443; Pearson and Lipman, Methods in Mol. Biol .
- affinity refers to the binding strength between an antibody or antigen-binding fragment thereof and an antigen, and may also be expressed as “binding strength”.
- X 1 in Formula 1 is Ala.
- X 2 of Formula 2 is Val.
- the heavy chain variable region of the present invention comprises at least one framework region (FR) selected from the group consisting of the following HFR1 to HFR4:
- HFR1 EVQLY 1 ESGGGLVQPGGSLRLSCY 2 AY 3 GFTFS (Y 1 is Val or Ala, Y 2 is Val or Ala, Y 3 is Ser or Arg)
- HFR2 WVRQY 4 PGKGLEWVS (Y 4 is Ala or Ser)
- HFR3 RY 5 TISRDNSKNTLYLQMNY 6 LRAEDTAVYYCAK (Y 5 is Ala or Thr and Y 6 is Ser or Asn)
- the heavy chain variable region of the present invention has an amino acid sequence selected from the group consisting of SEQ ID NOs: 19 to 22.
- the antibody or antigen-binding fragment thereof of the present invention comprises an LCDR1 region having the amino acid sequence of SEQ ID NO: 2; LCDR2 region having an amino acid sequence represented by the following general formula 3; and a light chain variable region comprising an LCDR3 region having the amino acid sequence of SEQ ID NO: 3:
- X 3 is Asn or Asp.
- X 3 is Asp.
- the light chain variable region of the present invention comprises one or more framework regions (FR) selected from the group consisting of the following LFR1 to LFR4:
- LFR1 SYELTQPPSVSVSPGQTASITC
- LFR2 WY 7 QQKPGQSPVTVIY (Y 7 is Phe or Tyr) (F or Y)
- HFR3 GIPERFSGSKSGNTATLTISGTQAMDEADYYC
- HFR4 FGGGTKLTVL
- the light chain variable region of the present invention has the amino acid sequence of SEQ ID NO: 4 or 18.
- the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to CD55, comprising the following light chain variable region and heavy chain variable region:
- the heavy chain variable region of SEQ ID NO: 5 is the heavy chain variable region of SEQ ID NO: 5; Or, in the heavy chain variable region of SEQ ID NO: 5, the 5th amino acid sequence V(Val) is substituted with A(Ala), the 23rd amino acid sequence A(Ala) is substituted with V(Val), the 25th amino acid sequence S(Ser) is substituted with R(Arg), 35th amino acid sequence A(Ala) is substituted with V(Val), 40th amino acid sequence A(Ala) is substituted with S(Ser), 68th amino acid
- the sequence A(Ala) is substituted with T(Thr), the 85th amino acid sequence S(Ser) is substituted with N(Asn), and the 101st amino acid sequence G(Gly) is V(Val), L(Leu) , I(Ile), F(Phe), M(Met), or a heavy chain variable region comprising one or more substitutions selected from the group consisting of substitutions with A(Ala).
- the present invention provides a nucleic acid molecule encoding the aforementioned antibody or antigen-binding fragment thereof of the present invention.
- nucleic acid molecule has a meaning comprehensively including DNA (gDNA and cDNA) and RNA molecules, and nucleotides, which are the basic structural units in nucleic acid molecules, include natural nucleotides as well as analogs with modified sugar or base sites. (analogue) (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical Reviews, (1990) 90:543-584).
- sequence of the nucleic acid molecule encoding the heavy and light chain variable regions of the present invention may be modified. Such modifications include additions, deletions, or non-conservative or conservative substitutions of nucleotides.
- the nucleic acid molecule of the present invention is construed to include a nucleotide sequence exhibiting substantial identity to the above-described nucleotide sequence.
- the substantial identity is at least 80% when the nucleotide sequence of the present invention and any other sequences are aligned as much as possible, and the aligned sequence is analyzed using an algorithm commonly used in the art. of homology, in one specific example, at least 90% homology, in another specific example, at least 95% homology.
- the present invention provides a composition for preventing or treating cancer comprising the above-described antibody or antigen-binding fragment thereof of the present invention as an active ingredient.
- the present invention provides a method for preventing or treating cancer, comprising administering to a subject a pharmaceutically effective amount of the aforementioned antibody or antigen-binding fragment thereof of the present invention.
- the present invention provides for use in therapy of the aforementioned antibody or antigen-binding fragment thereof of the present invention.
- prevention refers to inhibiting the occurrence of a disease or disease in a subject who has not been diagnosed as possessing the disease or disease, but is likely to be afflicted with the disease or disease.
- the term “treatment” refers to (a) inhibiting the development of a disease, disorder or condition; (b) alleviation of the disease, condition or condition; or (c) eliminating the disease, condition or symptom.
- the composition of the present invention When the composition of the present invention is administered to a subject, it restores the complement immune mechanism by inhibiting the activity of the CD55 receptor and inhibits the proliferation of cancer cells to inhibit cancer progression, or to eliminate or alleviate symptoms thereof. Therefore, the composition of the present invention may be a composition for cancer treatment by itself, or is administered with other pharmacological components, for example, a therapeutic agent having CDC (complement dependent cytotoxicity) as a mechanism of action to improve its therapeutic responsiveness. It can also be applied as an adjuvant. Accordingly, as used herein, the term “treatment” or “therapeutic agent” includes the meaning of “therapeutic adjuvant” or “therapeutic adjuvant”.
- administering refers to administering a therapeutically effective amount of the composition of the present invention directly to a subject so that the same amount is formed in the subject's body.
- the term "therapeutically effective amount” means the content of the composition in which the pharmacological component in the composition is sufficient to provide a therapeutic or prophylactic effect to an individual to whom the pharmaceutical composition of the present invention is administered, and thus " prophylactically effective amount”.
- the term "subject” includes, without limitation, a human, mouse, rat, guinea pig, dog, cat, horse, cow, pig, monkey, chimpanzee, baboon or rhesus monkey. Specifically, the subject of the present invention is a human.
- the composition further comprises at least one pharmacological component selected from the group consisting of an anti-CD20 antibody and a tyrosine kinase inhibitor.
- the anti-CD20 antibody is Rituximab.
- the tyrosine kinase inhibitor is selected from the group consisting of imatinib (Imatinib) and gefitinib (gefitinib).
- the cancer that can be prevented or treated by the composition of the present invention is a cancer that is CD55 positive.
- CD55-positive cancer refers to a carcinoma composed of cancer cells expressing the CD55 receptor, and specifically refers to a cancer in which CD55 is expressed enough to measurably inhibit complement immune activity in a subject. Accordingly, the term “CD55 positive cancer” is meant to include "CD55 overexpressing cancer”. According to the present invention, the composition of the present invention can eliminate drug resistance and enhance treatment sensitivity in various carcinomas in which resistance to a therapeutic agent is induced due to overexpression of CD55.
- CD55 positive cancers include, for example, melanoma, lymphoma, lung cancer, thyroid cancer, breast cancer, colorectal cancer, prostate cancer, head and neck cancer, stomach cancer, liver cancer, bladder cancer, kidney cancer, cervical cancer, pancreatic cancer, leukemia, bone marrow cancer, ovarian cancer, uterine cancer all solid and hematological cancers expressing CD55, including, but not limited to, cervical cancer, sarcoma, cholangiocarcinoma and endometrial cell carcinoma.
- the present invention provides a composition for diagnosis of cancer comprising the above-described antibody or antigen-binding fragment thereof of the present invention as an active ingredient.
- diagnosis includes determination of an individual's susceptibility to a particular disease, determination of whether an individual currently has a particular disease, and determination of the prognosis of a subject with a particular disease. do.
- the CD55 receptor is a typical cancer diagnostic marker showing a high expression level in cancer tissues compared to normal tissues, and the antibody of the present invention that specifically binds to CD55 can accurately determine the presence of a tumor in a biological sample.
- the antibody of the present invention accurately measures the expression level of CD55 in the tumor through various immunoassay methods to predict the therapeutic sensitivity of the tumor to the CDC drug, thereby establishing a customized treatment strategy according to the nature of the cancer at an early stage. can be usefully used for
- diagnosis composition refers to an integrated mixture or equipment comprising the antibody of the present invention as a means for measuring the expression level of CD55 protein in order to determine whether a subject has cancer or predict treatment sensitivity to a CDC drug. (device), which may be expressed as a “diagnostic kit”.
- biological sample means tissue, cells, whole blood, serum, plasma, saliva, urine, lymph, spinal fluid, tissue autopsy sample (brain, skin, lymph node, spinal cord, etc.), cell culture supernatant, ruptured eukaryotic cells and Bacterial expression systems include, but are not limited to.
- the detection of CD55 protein in a biological sample may be performed by a colormetric method, an electrochemical method, a fluorimetric method, a luminometry, a particle counting method, a visual assessment or Detection of antigen-antibody complex formation using a scintillation counting method can be performed.
- the term “detection” refers to a series of processes for determining whether an antigen-antibody complex is formed. Detection can be carried out using various labels including enzymes, fluorescent substances, ligands, luminescent substances, microparticles, or radioactive isotopes.
- Enzymes used as detection labels include, for example, acetylcholinesterase, alkaline phosphatase, ⁇ -D-galactosidase, horseradish peroxidase and ⁇ -latamase, and the fluorescent substance is fluoro Contains resinein, Eu 3+ , Eu 3+ chelate or cryptate, etc., as ligands, including biotin derivatives, etc., as luminescent materials, including acridinium esters and isoluminol derivatives, and the like, and as microparticles. colloidal gold and colored latex, and the like, and radioactive isotopes may include 57 Co, 3 H, 125 I and 125 I-Bonton Hunter reagents.
- the antigen-antibody complex can be detected using enzyme immunosorbent assay (ELISA).
- ELISA enzyme immunosorbent assay
- the antibody of the present invention may have a detection label, and when it does not have a detection label, the antibody of the present invention can be captured and confirmed by treating another antibody having a detection label.
- the present invention provides a bispecific antibody or a functional fragment thereof comprising the antigen-binding fragment of the present invention described above and an antigen-binding fragment of an antibody that specifically binds to CD20.
- bispecific antibody refers to an antibody comprising two different antigen-binding regions defined by different amino acid sequences. Typically, the two antigen binding regions comprised in a bispecific antibody are each specific for a different antigen or epitope.
- the bispecific antibody of the present invention is a single antibody (CD20 x CD55) molecule in which the aforementioned CD55-specific antigen-binding fragment of the present invention and another antigen-binding fragment that specifically recognizes CD20 are bound.
- the antigen-binding fragment of the anti-CD55 antibody contained in the bispecific antibody is in the form of scFv.
- the antigen-binding fragment of the antibody that specifically binds to CD55 includes scFv.
- the antigen-binding fragment of the antibody that specifically binds to CD55 is in the form of VL-linker-VH-CH2-CH3.
- the antigen-binding fragment of the anti-CD20 antibody contained in the bispecific antibody is in the form of Fab.
- the antigen-binding fragment of the antibody that specifically binds to CD20 includes Fab.
- the antigen-binding fragment of the antibody that specifically binds to CD20 is in the form of VL-CK-linker-VH-CH1-CH2-CH3.
- the antibody that specifically binds to CD20 is Rituximab (Rituximab).
- the bispecific antibody of the present invention may comprise an Fc region consisting of first and second subunits capable of stably associating.
- the term “Fc region” refers to the C-terminal region of an antibody heavy chain containing at least a portion of the constant region of a full-length antibody, and includes both a wild-type sequence Fc region and a mutant Fc region.
- the Fc region of an IgG comprises an IgG CH2 and an IgG CH3 domain.
- the CH3 region of a bispecific antibody of the invention has a wild-type or mutant CH3 domain (eg, an introduced “overhang” (“knob”) on one chain thereof and an introduced “cavity” corresponding to its other chain). (“hole”).
- the bispecific antibody of the present invention may use a knob-into-hole method to prevent unwanted pairing of CD20 X CD55 heavy chains with each other.
- the “knob-into-hole” method [US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996); Carter, J Immunol Meth 248, 7-15 (2001)] described a protrusion at the interface of a first polypeptide (“knob ”) and a cavity (“hole”) corresponding to the interface of the second polypeptide.
- the overhang is constructed by substituting a smaller amino acid side chain from the interface of the first polypeptide with a larger side chain (eg, tyrosine or tryptophan).
- a larger amino acid side chain eg, tyrosine or tryptophan
- a smaller side chain eg, alanine or threonine
- the bispecific antibody of the present invention comprises an antigen-binding fragment of an anti-CD55 antibody in the form of VL-linker-VH-CH2-CH3 and VL-CK-linker-VH-CH1-CH2-CH3 It may be a form to which an antigen-binding fragment of an anti-CD20 antibody is bound.
- the bispecific antibody of the present invention is composed of 10 to 100, more specifically 15 to 60 Gly and Ser in order to prevent unwanted pairing of CD20 X CD55 heavy chains.
- a linker may be used.
- the bispecific antibody of the present invention comprises CD55-scFv-knob (VL-linker20-VH-CH2-CH3) and CD20-Fab-hole (VL-CK-linker40-VH-CH1-CH2-CH3). It may be in a combined form.
- Linker20 includes 20 Glys or Sers, and examples thereof include, but are not limited to, Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser Gly Gly Gly Ser.
- linker40 includes 20 Gly or Ser, for example, Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Ser Gly Gly Ser Gly Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser Gly Ser may include, but is not limited thereto.
- the present invention provides an antibody or antigen-binding fragment thereof that specifically binds to CD55; And it provides a composition for prophylactic treatment and/or diagnosis of cancer comprising the same.
- the antibody of the present invention can be used as an effective therapeutic composition for various CD55-mediated diseases by showing high binding and inhibitory power to the CD55 protein that promotes tumor growth by suppressing the complement immune mechanism.
- the antibody of the present invention is effective for fundamentally eliminating drug resistance and remarkably improving treatment responsiveness in various diseases in which resistance to therapeutic agents with complement dependent cytotoxicity (CDC) as a mechanism of action is induced due to overexpression of CD55 It can be usefully used as a therapeutic adjuvant.
- CDC complement dependent cytotoxicity
- 1 is a diagram showing the results of ELISA analysis of the affinity of 4-1H and G4-1H to CD55.
- FIG. 2 is a diagram showing the results of ELISA analysis of the affinity for CD55 of an antibody prepared by screening from a library in which a random mutation is introduced in the gene of the G4-1H variable region.
- FIG. 3 is a diagram showing the results of ELISA analysis of the affinity for CD55 of an antibody prepared by substituting a hydrophobic amino acid for a key region to improve binding.
- FIG. 5a is a result of a FACS assay comparing the expression levels of CD20 and CD55 in Ramos and Ramos-RR.
- Figure 5b is a result of a FACS assay analyzing the killing effect of Ramos-RR cells by the combined treatment of rituximab and EP-10H antibody.
- FIG. 6a is a result of a FACS assay comparing CD55 expression levels in K562 and K562-IR.
- Figure 6b is a FACS assay result analyzing the killing effect of 562-IR cells by the combined treatment of imatinib and EP-10H antibody.
- FIG. 7a is a result of a FACS assay comparing CD55 expression levels in PC9 and PC9-GR.
- Figure 7b is a FACS assay result analyzing the killing effect of PC9-GR cells by the combined treatment of imatinib and EP-10H antibody.
- FIG. 8 is a diagram showing an antibody schematic diagram comparing the diabody type reported by SBU and Macor, which is a CD20 X CD55 diabody of the present invention.
- FIG. 10 shows the results of an ELISA assay measuring the affinity of the CD20 X CD55 diabody to CD20 ( FIG. 10A ) and CD55 ( FIG. 10B ), respectively.
- FIG. 11a shows the results of a FACS assay analyzing the killing effect of BJAB cells by the CD20 X CD55 diabody.
- FIG. 11b is a comparison result of BJAB cell death rates when treated with rituximab alone, rituximab and EP-10H antibody in combination, and CD20 X CD55 dual antibody treatment.
- 12A shows the results of a FACS assay analyzing the killing effect of Ramos cells by the CD20 X CD55 double antibody.
- 12B is a comparison result of Ramos cell death rates when treated with rituximab alone, rituximab and EP-10H antibody in combination, and CD20 X CD55 dual antibody treatment.
- 13A shows the results of a FACS assay analyzing the killing effect of Ramos-RR cells by the CD20 X CD55 double antibody.
- 13B is a comparison result of Ramos-RR cell death rates when rituximab alone, rituximab and EP-10H antibody combined, and CD20 X CD55 dual antibody treatment were performed.
- the amino acid residue numbering of antibody domains is determined by the Kabat EU numbering system, Kabat et al., "Sequences of Proteins of Immunological Interest", 5th Ed., U.S. Department of Health and Human Services, commonly used in the art. according to the EU index number as in NIH Publication No. 91-3242, 1991).
- the J gene of the light chain variable region was fixed with FGGGTKLTVL with reference to US2010-0056386, and the J gene of the heavy chain variable region was fixed with WGQGTTVTVSS with reference to US2014-0206849.
- the humanized 4-1H antibody was named G4-1H, and its base sequence is shown in Table 1.
- underlined text is a CDR region
- bold text indicates an amino acid substituted with the parent antibody (4-1H).
- the DNA of the variable region of the G4-1H antibody prepared in Example 1 was synthesized in the form of scFv (Cosmogenetech, Korea), and converted into a full-length IgG by PCR.
- scFv Cosmogenetech, Korea
- fragments of the variable and constant regions of the heavy and light chains from a pUC vector (Cosmogenetech, Korea) containing scFv were obtained through PCR using the V H , C H and V L , C K primer combinations of Table 2 below.
- PCR was performed using the HC and LC primer combinations shown in Table 2 below using the variable and constant regions of the obtained antibody, and as a result, the heavy and light chains of G4-1H were obtained.
- the heavy chain was ligated with Eco RI and Not I (New England Biolab, UK) enzymes and pCMV vector (ThermoFisher Scientific, USA), a vector for expression of animal cells treated with the same restriction enzyme.
- the light chain was treated using Xba I (New England Biolab, UK) enzyme and ligated into the pCMV vector treated with the same restriction enzyme.
- the ligation-completed plasmid was transformed by applying heat shock to DH5 ⁇ competent cells (New England Biolab, UK), and the obtained colonies were mass-cultured to obtain a plasmid.
- the plasmids of the heavy and light chains converted into complete antibodies were transduced into Expi293F cells (Invitrogen, USA) using polyethyleneimine (PEI) (Polysciences, USA) and 150 mM NaCl, and in Freestyle 293 expression medium (Invitrogen, USA). Suspended culture for 7 days in Erlenmeyer flasks at 37° C., 8% CO 2 and 55% humidity conditions. After centrifuging the expression cell culture solution at 4,000 rpm for 10 minutes, the supernatant was taken and filtered through a 0.22 ⁇ m filter. The filtered supernatant was induced to bind to 1 ml of MabSelect sure (GE Healthcare, USA) resin at 4°C.
- PKI polyethyleneimine
- Freestyle 293 expression medium Invitrogen, USA
- the bound resin was washed with 10 cv (column volume) of 20mM diphosphate and 500mM sodium chloride (pH 7.0) solution, and then the bound antibody was eluted using 100 mM citric acid (pH 3.0) solution, and then 1M Tris-HCL (pH 9.0) was neutralized.
- the size and purity of the light and heavy chains of the purified antibody were finally confirmed through SDS-PAGE after buffer exchange with pH 7.2 - 7.4 PBS using the Slide-A-Lyzer Dialysis cassette (ThermoFisher Scientific, USA). As a result, it was possible to confirm the molecular weight and high purity consistent with the theoretical calculated values.
- the binding ability of the G4-1H monoclonal antibody prepared in Example 2 to CD55 was confirmed by indirect ELISA.
- indirect ELISA recombinant human CD55 (R&D Systems, USA) was diluted at 1 ⁇ g/ml in 50 ⁇ l of PBS, placed in a 96-well immune plate (Corning, USA), and stored at 4° C. for adsorption overnight.
- Anti-human immunoglobulin Fc-HRP antibody (Jackson Immunoresearch, USA) was diluted 1:3,000 and treated at 50 ⁇ l per well, followed by reaction at room temperature for 1 hour. After the reaction, after washing 3 times with a buffer containing 0.5% Tween 20 (Amresco, USA), 3,3',5,5'-tetramethylbenzidine (TMB) (ThermoFisher Scientific, USA) 50 ⁇ l each and allowed to develop color for 10 minutes.
- TMB 3,3',5,5'-tetramethylbenzidine
- G4-1H showed a lower affinity for CD55 than 4-1H (FIG. 1).
- Example 4 Construction of a library in which random mutations are introduced in the gene of the variable region
- a library was constructed in which random mutations were introduced into the variable region gene of the G4-1H antibody through an error prone PCR process. Specifically, scFv sequencing primer 1 and primer 2, polymerase without proofreading function (Takara, Japan), polymerase buffer, dATP, dTTP, dCTP, and dGTP were added to pComb3x vector containing G4-1H scFv, and salt concentration and manganese were added. The mutation frequency was controlled by adjusting the amount.
- Error prone PCR was performed by repeating the procedure of 30 times of pre-heating at 94 ° C for 5 minutes, double helix separation at 91 ° C for 1 minute, primer binding at 55 ° C for 1 minute, and DNA synthesis reaction at 72 ° C for 3 minutes. A DNA synthesis reaction was performed at °C for 5 minutes.
- the purified PCR product and the phagemid vector, pComb3x vector, were digested using Sfi I (New England Biolab, UK) restriction enzyme, ligated, and then transformed into ER2738 E. coli and cultured.
- Clones having improved affinity for CD55 compared to G4-1H and 4-1H were selected through biopanning using the library prepared in Example 4 above.
- 192 clones selected from the plates of the 3rd and 4th biopanning products were placed in a 96 deep well plate with 100 ⁇ g/ml carbenicillin, 70 ⁇ g/ml kanamycin and VCSM13 helper phage, and incubated overnight at 37° C. was induced to proliferate in the expressed phage.
- the culture medium obtained above was centrifuged to obtain a medium supernatant containing phage, put it in an ELISA plate coated with recombinant human CD55 (R&D Systems 2009-CD/CF, USA), and incubated at 37 for 2 hours, and HRP was conjugated Anti-M13 antibody (Merck, USA) was used as a secondary antibody, and the antibody binding to CD55 was confirmed by ELISA.
- HRP was conjugated Anti-M13 antibody (Merck, USA) was used as a secondary antibody, and the antibody binding to CD55 was confirmed by ELISA.
- Using the phage of the 4-1H clone as a control 5 clones with higher binding affinity were selected.
- the antibody of Example 6 showed a higher affinity for CD55 compared to 4-1H ( FIG. 2 ).
- EP-1E, EP-1F, 3R-2-1H and EP-10H showed similar affinities, and EP-9B showed higher affinity than 4-1H but lower than other antibodies.
- Antibodies having a higher affinity for CD55 compared to 4-1H can be very usefully used for diagnosing various cancers or preparing pharmaceutical therapeutic compositions.
- variable region and constant region of the heavy chain were obtained by PCR using the HC1 and HC2 primer combinations in Table 4 from the pCMV vector containing the heavy chain variable region of EP-10H.
- the heavy chain variable region and constant region obtained through PCR were subjected to overlap PCR using HC3 forward primer and HC2 reverse primer to obtain VH-CH1-CH2-CH3 form.
- the heavy chain thus obtained was digested using Eco RI and Not I (New England Biolab, UK) restriction enzymes, and was ligated to pCMV vector (ThermoFisher Scientific, USA), which is a vector for expression of animal cells treated with the same restriction enzyme.
- the ligation-completed plasmid was transformed by applying heat shock to DH5 ⁇ Escherichia coli (New England Biolab, UK), followed by mass culture to obtain a plasmid.
- Example 9 Affinity analysis for CD55 of a complete antibody prepared by substituting a key region for improving binding affinity
- Example 8 The affinity of the antibody prepared in Example 8 to CD55 was confirmed by indirect ELISA. Indirect ELISA was performed in the same manner as in Example 3 described above.
- the antibody prepared by substituting a hydrophobic amino acid for the binding affinity core showed a higher affinity for CD55 than 4-1H (FIG. 3).
- 10H(A), 10H(I), 10H(L), 10H(F) and 10H(M) showed lower affinity than EP-10H. This means that the substitution of G with V at the H100A position represents the most efficient result for improving the binding force.
- BJAB is complement-resistant, due to the expression of CD55 (Golay, et al., Blood , 95(12):3900-8, 2000). For this reason, the responsiveness to rituximab, which is the main treatment mechanism for complement dependent cytotoxicity (CDC), is low.
- CDC complement dependent cytotoxicity
- apoptotic cells were identified with Attune NxT (ThermoFisher Scientific, USA), which is a FACS analysis equipment, and CDC was observed (FIG. 4).
- Attune NxT ThermoFisher Scientific, USA
- BJAB cells had low reactivity to rituximab, but their effect was increased when co-administered with anti-CD55 antibodies (4-1H and EP-10H), and the width of the increased effect was similar to that of rituximab.
- the combination of rituximab and EP-10H was greater than that in combination with 4-1H.
- Ramos was a rituximab-responsive B-cell lymphoma cell line, and an experiment was performed as follows to confirm CD55 expression in Ramos-RR, a rituximab-resistant cell line prepared using Ramos.
- the fluorescently stained cells were washed with PBS and then suspended in 400 ⁇ l of PBS and analyzed using Attune NxT (ThermoFisher Scientific, USA), which is a FACS analysis equipment, and the results are shown in FIG. 5a.
- Attune NxT ThermoFisher Scientific, USA
- K562 is a leukemia cell line that is responsive to imatinib, a tyrosine kinase inhibitor.
- CD55 expression in K562-IR, an imatinib-resistant cell line prepared using K562 was confirmed in the same manner as in Experimental Example 10-2a. As a result, it was confirmed that the CD55 expression of K562-IR was increased compared to that of K562 (FIG. 6a). This means that CD55 is involved in drug resistance of imatinib.
- each of EP-10H was diluted with RPMI medium to a concentration of 10 ⁇ g/ml, treated with a final 500 ⁇ l, and cultured at 37° C., 5% CO 2 conditions for 24 hours. Thereafter, apoptotic cells were analyzed with Attune NxT, a FACS analysis equipment, using 7-AAD and FITC Annexin V Apoptosis Detection Kit (FIG. 6b).
- Imatinib is a long-term drug widely used for the treatment of leukemia, and a strategy to overcome drug resistance that may be induced by long-term administration is urgently needed. Accordingly, the strategy of overcoming the resistance of imatinib using EP-10H is expected to be very effective in treating leukemia.
- PC9 is a non-small cell lung cancer (NSCLC) cell line that is responsive to the tyrosine kinase inhibitor gefitinib.
- NSCLC non-small cell lung cancer
- NSCLC cell lines PC9 and CD55 overexpressed PC9-GR which exhibits resistance to gefitinib, were aliquoted into 1 x 10 5 per well in a 12-well cell culture plate, and then cultured at 37° C. and 5% CO 2 conditions. 24 hours after dispensing, 5 ⁇ g/ml of gefitinib, and 5 ⁇ g/ml of gefitinib and 4-1H or EP-10H, respectively, were diluted with RPMI medium to 5 ⁇ g/ml to confirm the effect of co-administration, and the final 500 ⁇ l After treatment, it was cultured again at 37° C., 5% CO 2 conditions for 24 hours. Thereafter, apoptotic cells were analyzed with Attune NxT, a FACS analysis equipment, using 7-AAD and FITC Annexin V Apoptosis Detection Kit (FIG. 7b).
- Gefitinib is an effective drug for NSCLC for which there are not many therapeutic agents, and when drug resistance develops in a situation where there are not many other therapeutic options, it is difficult to select a second drug, so a strategy to overcome this drug resistance is urgently needed.
- the strategy of overcoming resistance to gefitinib using EP-10H is expected to be very effective in treating NSCLC.
- Example 10 the combined effect of EP-10H and various drugs was confirmed. Based on the results of the combination effect with rituximab confirmed in Experimental Examples 10-1 and 2 of Example 10, a method of using two antibodies targeting different antigens in combination, and a method of using one antibody to simultaneously target two antigens In order to compare the cancer cell killing ability of the double antibody, a CD20 x CD55 double antibody was prepared using rituximab and EP-10H.
- the SBU-type CD20 X CD55 diabody used a knob-into-hole technique to prevent undesirable binding of heavy chains to each other, and a linker composed of Gly and Ser was used to prevent erroneous binding between light chains. Cloning was carried out in the form of CD55-scFv-knob (VL-linker20-VH-CH2-CH3) and CD20-Fab-hole (VL-CK-linker40-VH-CH1-CH2-CH3), respectively, and CD55-scFv-knob In the case of EP-10H prepared in Example 6 was used as a template, and PCR was performed using the primer combinations in Table 8.
- the amplified genome was treated with Bss HII and Xba I (New England Biolab, UK) enzymes, and was ligated to pMAZ vector, a vector for expression of animal cells treated with the same restriction enzyme.
- the ligation-completed plasmid was transformed by applying heat shock to DH5 ⁇ competent cells (New England Biolab, UK), and the obtained colonies were mass-cultured to obtain a plasmid.
- CD20-Fab-hole VL-CK-linker40-VH-CH1-CH2-CH3
- PCR was performed using the primer combinations in Table 9 based on the rituximab sequence published in the Drug Data Bank.
- the amplified genome was treated with Bss HII and Xba I enzymes, and was ligated to pMAZ vector, a vector for expression of animal cells treated with the same restriction enzyme.
- the ligation-completed plasmid was transformed by applying heat shock to a DH5 ⁇ competent cell (New England Biolab, UK), and the obtained colonies were mass-cultured to obtain a plasmid and sequence analysis (Table 10) was completed.
- the SBU of the present invention uses a linker composed of Gly and Ser to prevent erroneous binding of light chains, so that double antibody expression is possible with two types of DNA.
- the supernatant was taken and filtered through a 0.22 ⁇ m filter. The filtered supernatant was induced to bind to 1 ml of KappaSelect (GE Healthcare, USA) resin at 4°C.
- the bound resin was washed with a PBS solution of 10 cv (column volume), and then the bound antibody was eluted using a 100 mM glycine-HCl (pH 2.7) solution, and then neutralized with 1 M Tris-HCL (pH 9.0). .
- the size and purity of the light and heavy chains of the purified antibody were confirmed through SDS-PAGE. As a result, molecular weight and high purity consistent with the theoretical calculated values were confirmed (FIG. 9).
- the SBU-type diabody is a hetero form in which the CD20 binding site is Fab and the CD55 binding site is scFv.
- Knob-knob homodimer or knob monomer known to be most likely to be generated during dual antibody purification when purified with protein L using the C kappa portion of the Fab (Giese, et al., Biotechnol Prog , 34(2)397-404) It is possible to suppress the production of , and only the heterodimer in the desired form can be obtained.
- the CD20 X CD55 diabody which can be used as a treatment for hematologic cancers in which CD20 is overexpressed
- the CD20 X CD55 diabody in the form of SBU which has a higher affinity for CD20, will be more effective.
- the apoptosis ability of the CD20 X CD55 double antibody was confirmed by the method of Experimental Example 10-1.
- 20 ⁇ g/ml of rituximab for 5x10 5 BJAB cells per sample, 20 ⁇ g/ml of EP-10H and rituximab, respectively, to confirm the effect of co-administration, and the CD20 X CD55 diabody, the form disclosed in the prior literature written by Macor and SBU forms were diluted with RPMI medium supplemented with 20% complement sera human (Sigma, USA) at a concentration of 20 ⁇ g/ml, respectively, and the final 100 ⁇ l was treated. Others were performed in the same manner as in Experimental Example 10-1.
- the CD20 X CD55 diabody showed a significant difference in apoptosis compared to the control treated with complement sera human only, and SBU showed a significant difference in cell death compared to rituximab. showed apoptosis ( FIGS. 11A and 11B ).
- the apoptosis ability of the CD20 X CD55 dual antibody was confirmed in the Ramos cell line by the method of Experimental Example 11-4 ( FIGS. 12A and 12B ).
- the CD20 X CD55 double antibody showed a significant difference in apoptosis compared to rituximab.
- the SBU of the present invention showed superior apoptosis ability than the dual antibody of Macor.
- CD20 X CD55 diabody can exhibit more effective anticancer effects than rituximab in rituximab-responsive carcinoma, and that SBU can be applied as an effective therapeutic agent among CD20 x CD55 diabodies in CD20-expressing hematologic cancers. do.
- the apoptosis ability of the CD20 X CD55 dual antibody was confirmed in the Ramos-RR cell line by the method of Experimental Example 11-4 ( FIGS. 13a and 13b ).
- the CD20 X CD55 dual antibody showed a significant difference in apoptosis compared to rituximab.
- the SBU of the present invention showed a significantly superior apoptosis activity than the Macor double antibody among the diabodies.
- CDC activation was analyzed by taking the supernatant treated with rituximab and CD20 X CD55 dual antibody in the form of SBU before flow cytometry analysis of the Ramos-RR cell pellet (FIG. 14).
- the CDC mechanism is a reaction that occurs through the binding of C1q to an antibody, and activation analysis is possible at an intermediate stage in the entire CDC process based on the production of C4d, a by-product thereof.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
경쇄 가변영역 | ||
G4-1H (VL) |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWYQQKPGQSPVTVIYWNDKRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVL | 서열번호 4 |
중쇄 가변영역 | ||
G4-1H (VH) |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNAGAGGWHAAYIDAWGQGTTVTVSS | 서열번호 5 |
프라이머 | 서열 | 서열번호 | |
VH | 정방향 | CTT CCT GTC AGT AAC TAC AGG TGT CCA CTC CCA GGT GCA ACT GCA GCA GTC | 6 |
역방향 | CCA GCG TGA CCG TAT CCA GCG CCT CCA CCA AGG GCC CCA | 7 | |
CH | 정방향 | GCC TCC ACC AAG GGC CC | 8 |
역방향 | TCC CCC GGC AAG TGA GCG GCC GCT CAC | 9 | |
HC | 정방향 | CAG AAT TCA CTC TAA CCA TGG AAT GGA GCT GGG TCT TTC TCT TCT TCC TGT CAG TAA CTA CAG | 10 |
역방향 | TCC CCC GGC AAG TGA GCG GCC GCT CAC | 9 | |
VL | 정방향 | GGT CTT TGT ATA CAT GTT GCT GTG GTT GTC TGG TGT TGA AGG AAG CTA CGA GCT GAC AC | 11 |
역방향 | CAA GCT CAC CGT CTT GCG GAC CGT GGC C | 12 | |
CK | 정방향 | CGG ACC GTG GCC GCC CCC TC | 13 |
역방향 | CGG GGC GAG TGC TAG TTC TAG AAC TA | 14 | |
LC | 정방향 | GGG AAT TCT AGA GGA TCG AAC CCT TTG CAA GCT TCG GCA CGA GCA GAC CAG CAT GGG CAT CAA GAT GGA GAC ACA TTC TCA GGT CTT TGT ATA CAT GTT G | 15 |
역방향 | CGG GGC GAG TGC TAG TTC TAG AAC TA | 14 |
scFv 시퀀싱 프라이머 | ||
1 | ACA CTT TAT GCT TCC GGC | 서열번호 16 |
2 | CAA AAT CAC CGG AAC CAG AG | 서열번호 17 |
아미노산 | 서열번호 | |
EP-1E 경쇄 가변영역 |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWFQQKPGQSPVTVIYWN N KRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVL | 18 |
EP-1E 중쇄 가변영역 |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNA V AGGWHAAYIDAWGQGTTVTVSS | 19 |
EP-1F 경쇄 가변영역 |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWYQQKPGQSPVTVIYWNDKRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVL | 4 |
EP-1F 중쇄 가변영역 |
EVQLAESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNA V AGGWHAAYIDAWGQGTTVTVSS | 20 |
EP-9B 경쇄 가변영역 |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWYQQKPGQSPVTVIYWNDKRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVL | 4 |
EP-9B 중쇄 가변영역 |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGM V WVRQSPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNNLRAEDTAVYYCAKNA V AGGWHAAYIDAWGQGTTVTVSS | 21 |
3R-2-1H 경쇄 가변영역 |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWYQQKPGQSPVTVIYWNDKRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVL | 4 |
3R-2-1H 중쇄 가변영역 |
EVQLVESGGGLVQPGGSLRLSCVARGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRTTISRDNSKNTLYLQMNSLRAEDTAVYYCAKNA V AGGWHAAYIDAWGQGTTVTVSS | 22 |
EP-10H 경쇄 가변영역 |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWYQQKPGQSPVTVIYWNDKRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVL | 4 |
EP-10H 중쇄 가변영역 |
EVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNA V AGGWHAAYIDAWGQGTTVTVSS | 19 |
프라이머 | 서열 | 서열번호 | |
VL | 정방향 | GGT CTT TGT ATA CAT GTT GCT GTG GTT GTC TGG TGT TGA AGG AAG CTA CGA GCT GAC AC | 11 |
역방향 | CAA GCT CAC CGT CTT GCG GAC CGT GGC C | 12 | |
CK | 정방향 | CGG ACC GTG GCC GCC CCC TC | 13 |
역방향 | CGG GGC GAG TGC TAG TTC TAG AAC TA | 14 | |
LC | 정방향 | GGG AAT TCT AGA GGA TCG AAC CCT TTG CAA GCT TCG GCA CGA GCA GAC CAG CAT GGG CAT CAA GAT GGA GAC ACA TTC TCA GGT CTT TGT ATA CAT GTT G | 15 |
역방향 | CGG GGC GAG TGC TAG TTC TAG AAC TA | 14 | |
VH | 정방향 | CTT CCT GTC AGT AAC TAC AGG TGT CCA CTC CGA GGT CCA GCT GGT C | 23 |
역방향 | GTG ACC GTG TCC AGC GCC TCC ACC AAG GG | 24 | |
CH | 정방향 | GCC TCC ACC AAG GGC CC | 8 |
역방향 | TCC CCC GGC AAG TGA GCG GCC GCT CAC | 9 | |
HC | 정방향 | CAG AAT TCA CTC TAA CCA TGG AAT GGA GCT GGG TCT TTC TCT TCT TCC TGT CAG TAA CTA CAG | 10 |
역방향 | TCC CCC GGC AAG TGA GCG GCC GCT CAC | 9 |
아미노산 | 서열번호 | |
10H(A) 중쇄 가변영역 | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNAAAGGWHAAYIDAWGQGTTVTVSS | 25 |
10H(I) 중쇄 가변영역 | EVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNAIAGGWHAAYIDAWGQGTTVTVSS | 26 |
10H(L) 중쇄 가변영역 | EVQLAESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNALAGGWHAAYIDAWGQGTTVTVSS | 27 |
10H(F) 중쇄 가변영역 | EVQLAESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNAFAGGWHAAYIDAWGQGTTVTVSS | 28 |
10H(M) 중쇄 가변영역 | EVQLAESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNAMAGGWHAAYIDAWGQGTTVTVSS | 29 |
프라이머 | 서열 | 서열번호 | |
HC1 | 정방향 | CTT CCT GTC AGT AAC TAC AGG TGT CCA CTC CGA GGT CCA GCT GGT C | 23 |
역방향 | GTA CTA CTG CGC CAA G | 30 | |
HC2 | 정방향1 | GTA CTA CTG CGC CAA GAA CGC CGC GGC CGG GGG GTG GCA CGC | 31 |
정방향2 | GTA CTA CTG CGC CAA GAA CGC CAT TGC CGG GGG GTG GCA CGC | 32 | |
정방향3 | GTA CTA CTG CGC CAA GAA CGC CCT GGC CGG GGG GTG GCA CGC | 33 | |
정방향4 | GTA CTA CTG CGC CAA GAA CGC CAT GGC CGG GGG GTG GCA CGC | 34 | |
정방향5 | GTA CTA CTG CGC CAA GAA CGC CTT TGC CGG GGG GTG GCA CGC | 35 | |
역방향 | TCC CCC GGC AAG TGA GCG GCC GCT CAC | 9 | |
HC3 | 정방향 | CAG AAT TCA CTC TAA CCA TGG AAT GGA GCT GGG TCT TTC TCT TCT TCC TGT CAG TAA CTA CAG | 10 |
역방향 | TCC CCC GGC AAG TGA GCG GCC GCT CAC | 9 |
프라이머 | 서열 | 서열번호 | |
VL | 정방향 | CAG CGC GCA CTC CAG CTA CGA GCT GAC ACA GCC | 36 |
역방향 | GAC CAA GCT CAC CGT CTT GGG CGG AGG CGG GAG TGG TGG TGG CGG TAG CGG TGG AGG AGG C | 37 | |
VH | 정방향 | GTG GAG GAG GCA GTG GAT CTG GCG GCT CTG AGG TCC AGC TGG TCG | 38 |
역방향 | GGC ACA ACC GTG ACC GTG TCC AGC GGC GGC TCA GAC AAA ACT CAC AC | 39 | |
CH | 정방향 | CGT GTC CAG CGG CGG CTC AGA CAA AAC TCA CAC ATG C | 40 |
역방향 | CTC TCC CTG TCC CCG GGT AAA TGA CTA GAA CTA | 41 |
프라이머 | 서열 | 서열번호 | |
VL-CK | 정방향 | CGC AGC GAG CGC GCA CTC CCA GAT TGT CCT GTC TCA GTC TCC TGC | 42 |
역방향 | CGG CCG CCG TGC GAG ATC TTT TGA TTT CCA GTT TAG TTC CGC CG | 43 | |
VH | 정방향 | CAA GTC CAA CTG CAA CAA CCG GG | 44 |
역방향 | GGA AGA CCG ATG GGC CCT TGA AGC TAG CGG CGG AAA CCG TTG TGC CAG AG | 45 | |
CH | 정방향 | GCA AGC TTC AAG GGC | 46 |
역방향 | CTC TCC CTG TCC CCG GGT AAA TGA CTA GAA CTA | 41 |
CD55- scFv-knob |
SYELTQPPSVSVSPGQTASITCSGGGGSYGWYQQKPGQSPVTVIYWNDKRPSGIPERFSGSKSGNTATLTISGTQAMDEADYYCGGWDSSTYAIFGGGTKLTVLGGGGSGGGGSGGGGSGSGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDRGMAWVRQAPGKGLEWVSGISSSGRYTYYAPAVKGRATISRDNSKNTLYLQMNSLRAEDTAVYYCAKNAVAGGWHAAYIDAWGQGTTVTVSSGGSDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK | 서열번호 47 |
CD20-Fab-hole | QIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIKRSRTAAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSGSGGSGGGGSGGGGSGGGGSGSGSSQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSAASFKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK | 서열번호 48 |
Claims (21)
- 하기 일반식 1로 표시되는 아미노산 서열을 가지는 HCDR1 영역; 서열목록 제1서열의 아미노산 서열을 가지는 HCDR2 영역; 및 하기 일반식 2로 표시되는 아미노산 서열을 가지는 HCDR3 영역을 포함하는 중쇄 가변영역을 포함하는, CD55에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편:일반식 1D-R-G-M-X1;일반식 2N-A-X2-A-G-G-W-H-A-A-Y-I-D-A,상기 일반식 1에서 X1은 Ala 또는 Val이며, 상기 일반식 2에서 X2는 Val, Ala, Ile, Leu, Phe 및 Met로 구성된 군으로부터 선택된다.
- 제 1 항에 있어서, 상기 X1은 Ala인 것을 특징으로 하는 항체 또는 이의 항원 결합 단편.
- 제 1 항에 있어서, 상기 X2는 Val인 것을 특징으로 하는 항체 또는 이의 항원 결합 단편.
- 제 1 항에 있어서, 상기 항체 또는 이의 항원 결합 단편은 서열목록 제2서열의 아미노산 서열을 가지는 LCDR1 영역; 하기 일반식 3으로 표시되는 아미노산 서열을 가지는 LCDR2 영역; 및 서열목록 제3서열의 아미노산 서열을 가지는 LCDR3 영역을 포함하는 경쇄 가변영역을 추가적으로 포함하는 것을 특징으로 하는 항체 또는 이의 항원 결합 단편:일반식 3W-N-X3-K-R-P-S,상기 일반식 3에서 X3는 Asn 또는 Asp이다.
- 제 4 항에 있어서, 상기 X3는 Asp인 것을 특징으로 하는 항체 또는 이의 항원 결합 단편.
- 하기의 경쇄 가변영역 및 중쇄 가변영역을 포함하는, CD55에 특이적으로 결합하는 항체 또는 이의 항원 결합 단편:a) 서열목록 제4서열의 경쇄 가변영역; 또는 상기 서열목록 제4서열의 경쇄 가변영역에서 32번째 아미노산 서열인 Y(Tyr)가 F(Phe)로 치환 및 48번째 아미노산 서열인 D(Asp)가 N(Asn)으로 치환으로 구성된 군으로부터 선택되는 1 이상의 치환을 포함하는 경쇄 가변영역, 및b) 서열목록 제5서열의 중쇄 가변영역; 또는 상기 서열목록 제5서열의 중쇄 가변영역에서 5번째 아미노산 서열인 V(Val)가 A(Ala)로 치환, 23번째 아미노산 서열인 A(Ala)가 V(Val)로 치환, 25번째 아미노산 서열인 S(Ser)가 R(Arg)로 치환, 35번째 아미노산 서열인 A(Ala)가 V(Val)로 치환, 40번째 아미노산 서열인 A(Ala)가 S(Ser)로 치환, 68번째 아미노산 서열인 A(Ala)가 T(Thr)로 치환, 85번째 아미노산 서열인 S(Ser)가 N(Asn)로 치환 및 101번째 아미노산 서열인 G(Gly)가 V(Val), L(Leu), I(Ile), F(Phe), M(Met) 또는 A(Ala)로 치환으로 구성된 군으로부터 선택되는 1 이상의 치환을 포함하는 중쇄 가변영역.
- 제 1 항 또는 제 6 항에 있어서, 상기 항원 결합 단편은 scFv, Fab 단편, F(ab') 단편, F(ab')2 단편 또는 Fv 단편인 것을 특징으로 하는 항체 또는 이의 항원 결합 단편.
- 제 1 항 내지 제 6 항 중 어느 한 항의 항체 또는 이의 항원 결합 단편을 코딩하는 핵산분자.
- 제 1 항 내지 제 6항 중 어느 한 항의 항체 또는 이의 항원 결합 단편을 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물.
- 제 9 항에 있어서, 상기 조성물은 항-CD20 항체 및 티로신 키나아제 억제제로 구성된 군으로부터 선택되는 하나 이상의 약리성분을 추가적으로 포함하는 것을 특징으로 하는 조성물.
- 제 10 항에 있어서, 상기 항-CD20 항체는 리툭시맙(Rituximab)인 것을 특징으로 하는 조성물.
- 제 10 항에 있어서, 상기 티로신 키나아제 억제제는 이마티닙(Imatinib) 및 게피티닙(gefitinib)으로 구성된 군으로부터 선택되는 하나 이상의 억제제인 것을 특징으로 하는 조성물.
- 제 9 항에 있어서, 상기 암은 CD55 양성인 암인 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 6 항 중 어느 한 항의 항체 또는 이의 항원 결합 단편을 유효성분으로 포함하는 암의 진단용 조성물.
- 제 14 항에 있어서, 상기 암은 CD55 양성인 암인 것을 특징으로 하는 조성물.
- 제 1 항 내지 제 6항 중 어느 한 항의 CD55에 특이적으로 결합하는 항체의 항원 결합 단편 및 CD20에 특이적으로 결합하는 항체의 항원 결합 단편을 포함하는 이중특이적 항체 또는 이의 기능적 단편.
- 제 16 항에 있어서, 상기 CD20에 특이적으로 결합하는 항체는 리툭시맙(Rituximab)인 것을 특징으로 하는 이중특이적 항체 또는 이의 기능적 단편.
- 제 16 항에 있어서 상기 CD55에 특이적으로 결합하는 항체의 항원 결합 단편은 scFv를 포함하는 것을 특징으로 하는 이중특이적 항체 또는 이의 기능적 단편.
- 제 16 항에 있어서 상기 CD55에 특이적으로 결합하는 항체의 항원 결합 단편은 VL-링커-VH-CH2-CH3 형태인 것을 특징으로 하는 이중특이적 항체 또는 이의 기능적 단편.
- 제 16 항에 있어서 상기 CD20에 특이적으로 결합하는 항체의 항원 결합 단편은 Fab를 포함하는 것을 특징으로 하는 이중특이적 항체 또는 이의 기능적 단편.
- 제 16 항에 있어서 상기 CD20에 특이적으로 결합하는 항체의 항원 결합 단편은 VL-CK-링커-VH-CH1-CH2-CH3 형태인 것을 특징으로 하는 이중특이적 항체 또는 이의 기능적 단편.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280013631.XA CN116964094A (zh) | 2021-01-12 | 2022-01-12 | 针对cd55的新型抗体及其用途 |
US18/271,958 US20240141061A1 (en) | 2021-01-12 | 2022-01-12 | Novel antibody against cd55 and use thereof |
JP2023541074A JP2024502129A (ja) | 2021-01-12 | 2022-01-12 | Cd55に対する新規抗体及びその用途 |
EP22739667.8A EP4279510A1 (en) | 2021-01-12 | 2022-01-12 | Novel antibody to cd55 and uses thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20210004196 | 2021-01-12 | ||
KR10-2021-0004196 | 2021-01-12 | ||
KR1020220001356A KR20220102114A (ko) | 2021-01-12 | 2022-01-05 | Cd55에 대한 신규 항체 및 이의 용도 |
KR10-2022-0001356 | 2022-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022154472A1 true WO2022154472A1 (ko) | 2022-07-21 |
Family
ID=82447326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2022/000551 WO2022154472A1 (ko) | 2021-01-12 | 2022-01-12 | Cd55에 대한 신규 항체 및 이의 용도 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240141061A1 (ko) |
EP (1) | EP4279510A1 (ko) |
JP (1) | JP2024502129A (ko) |
WO (1) | WO2022154472A1 (ko) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007086A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
WO1988007085A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Process for the purification of recombinant polypeptides |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
WO2006117782A2 (en) * | 2005-05-04 | 2006-11-09 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
US20100056386A1 (en) | 2007-09-14 | 2010-03-04 | Adimab, Inc. | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor |
US20140206849A1 (en) | 2010-04-30 | 2014-07-24 | Alexion Pharmaceuticals, Inc. | Antibodies having reduced immunogenicity in a human |
KR20160132333A (ko) | 2014-03-28 | 2016-11-17 | 가부시키가이샤 시마세이키 세이사쿠쇼 | 슈즈 어퍼 및 슈즈 어퍼의 편성방법 |
KR101800774B1 (ko) | 2016-10-12 | 2017-11-24 | 한국원자력연구원 | 암 진단 및 치료용 cd55 표적 항체 및 이의 용도 |
KR20180040842A (ko) * | 2016-10-13 | 2018-04-23 | 한국원자력연구원 | 암 표적 치료를 위한 방사성 동위원소가 표지된 cd55 표적 항체 및 이의 용도 |
-
2022
- 2022-01-12 JP JP2023541074A patent/JP2024502129A/ja active Pending
- 2022-01-12 EP EP22739667.8A patent/EP4279510A1/en active Pending
- 2022-01-12 WO PCT/KR2022/000551 patent/WO2022154472A1/ko active Application Filing
- 2022-01-12 US US18/271,958 patent/US20240141061A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007086A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Leader sequences for the production of recombinant proteins |
WO1988007085A1 (en) | 1987-03-20 | 1988-09-22 | Creative Biomolecules, Inc. | Process for the purification of recombinant polypeptides |
WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US7695936B2 (en) | 1995-03-01 | 2010-04-13 | Genentech, Inc. | Knobs and holes heteromeric polypeptides |
WO2006117782A2 (en) * | 2005-05-04 | 2006-11-09 | Quark Pharmaceuticals, Inc. | Recombinant antibodies against cd55 and cd59 and uses thereof |
US20100056386A1 (en) | 2007-09-14 | 2010-03-04 | Adimab, Inc. | Rationally Designed, Synthetic Antibody Libraries and Uses Therefor |
US20140206849A1 (en) | 2010-04-30 | 2014-07-24 | Alexion Pharmaceuticals, Inc. | Antibodies having reduced immunogenicity in a human |
KR20160132333A (ko) | 2014-03-28 | 2016-11-17 | 가부시키가이샤 시마세이키 세이사쿠쇼 | 슈즈 어퍼 및 슈즈 어퍼의 편성방법 |
KR101800774B1 (ko) | 2016-10-12 | 2017-11-24 | 한국원자력연구원 | 암 진단 및 치료용 cd55 표적 항체 및 이의 용도 |
KR20180040842A (ko) * | 2016-10-13 | 2018-04-23 | 한국원자력연구원 | 암 표적 치료를 위한 방사성 동위원소가 표지된 cd55 표적 항체 및 이의 용도 |
Non-Patent Citations (19)
Title |
---|
CARTER, J IMMUNOL METH, vol. 248, 2001, pages 7 - 15 |
CORPET ET AL., NUC. ACIDS RES., vol. 16, 1988, pages 10881 - 90 |
DATABASE PROTEIN 1 December 2020 (2020-12-01), ANONYMOUS : "IGH c739_heavy_IGHV3-23_IGHD4-17_IGHJ4, partial [Homo sapiens]", XP055950826, retrieved from NCBI Database accession no. QEP15014 * |
DATABASE PROTEIN 17 September 2019 (2019-09-17), ANONYMOUS : "IGL c2238_light_IGLV3-1_IGLJ2, partial [Homo sapiens]", XP055950828, retrieved from NCBI Database accession no. QEP12299 * |
GIESE ET AL., BIOTECHNOL PROG, vol. 34, no. 2, pages 397 - 404 |
GOLAY ET AL., BLOOD, vol. 95, no. 12, 2000, pages 3900 - 8 |
HIGGINSSHARP, CABIOS, vol. 5, 1989, pages 151 - 3 |
HIGGINSSHARP, GENE, vol. 73, 1988, pages 237 - 44 |
HUANG ET AL., COMP. APPL. BIOSCI., vol. 8, 1992, pages 155 - 65 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, pages: 91 - 3242 |
MACOR ET AL., LEUKEMIA, vol. 29, no. 2, 2014, pages 406 - 14 |
MOORE ET AL.: "A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats", METHODS, vol. 154, pages 38 - 50, XP055625796, DOI: 10.1016/j.ymeth.2018.10.006 |
NEEDLEMANWUNSCH, J. MOL. BIO., vol. 48, 1970, pages 443 |
PEARSON ET AL., METH. MOL. BIOL., vol. 24, 1994, pages 307 - 31 |
PEARSONLIPMAN, METHODS IN MOL. BIOL., vol. 24, 1988, pages 307 - 31 |
RIDGWAY ET AL., PROT ENG, vol. 9, 1996, pages 617 - 621 |
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY |
SMITHWATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482 |
UHLMANPEYMAN, CHEMICAL REVIEWS, vol. 90, 1990, pages 543 - 584 |
Also Published As
Publication number | Publication date |
---|---|
EP4279510A1 (en) | 2023-11-22 |
US20240141061A1 (en) | 2024-05-02 |
JP2024502129A (ja) | 2024-01-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020111913A1 (en) | Anti-4-1bb antibody and use thereof | |
WO2019098682A1 (ko) | 항-her2 항체 또는 그의 항원 결합 단편, 및 이를 포함하는 키메라 항원 수용체 | |
WO2019225777A1 (ko) | 항-ror1 항체 및 그 용도 | |
WO2017052241A1 (en) | Novel anti-mesothelin antibody and composition comprising the same | |
WO2019225787A1 (ko) | 항-b7-h3 항체 및 그 용도 | |
WO2015005632A1 (ko) | Dll4와 vegf에 특이적으로 결합하는 신규 이중표적 단백질 및 이의 용도 | |
WO2014119969A1 (ko) | 보체 관련 질환의 예방 및 치료를 위한 c5 항체 및 방법 | |
WO2022039490A1 (en) | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof | |
WO2020005003A1 (ko) | Lag-3에 특이적으로 결합하는 단클론항체 및 이의 용도 | |
WO2021091359A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2019132533A1 (ko) | 항-pd-l1 항체 및 이의 용도 | |
WO2021210939A1 (ko) | 항-her2 어피바디 및 이를 스위치 분자로 이용하는 스위처블 키메라 항원 수용체 | |
WO2024049161A1 (ko) | 신규한 항-pd-l1 키메릭 항원 수용체 및 이를 발현하는 면역세포 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
WO2022154472A1 (ko) | Cd55에 대한 신규 항체 및 이의 용도 | |
WO2020004934A1 (ko) | 항-bcma 항체 및 그 용도 | |
WO2020116963A1 (ko) | 엔도텔린 수용체 a 활성 조절 항체 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2022216014A1 (ko) | 항-cntn4 항체 및 그의 용도 | |
KR20220102114A (ko) | Cd55에 대한 신규 항체 및 이의 용도 | |
WO2020242200A1 (ko) | 엔도텔린 수용체 a 결합력이 향상된 항체 | |
WO2020141869A1 (ko) | Icam-1에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2017142294A1 (ko) | EGFRvIII에 대한 항체 및 이의 용도 | |
WO2019093807A2 (ko) | Il-17a 에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2023195810A1 (en) | Pharmaceutical composition for treating or preventing cancer with low expression level of her2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22739667 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023541074 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18271958 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280013631.X Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022739667 Country of ref document: EP Effective date: 20230814 |